VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...
Hosted on MSN
ASBP: A platform approach to drug delivery with an unconventional path to commercialization
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is attempting something relatively uncommon in the biotech space: building a pharmaceutical platform while simultaneously testing commercialization ...
Sublingual medications dissolve under your tongue and absorb directly into your bloodstream through the tissue there, bypassing digestion. Common sublingual medications include nitroglycerin spray, ...
Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...
Near-Instant Absorption: Bypasses the gastrointestinal tract and first-pass metabolism, potentially reducing onset of action from 30 minutes to just minutes. Clinical Comparability: Designed to mirror ...
A Prescription Drug User Fee Act target date of January 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for epinephrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results